ArticleEuropean journal of nuclear medicine and molecular imaging2025
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- The predictive value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinoma.Frontiers in nuclear medicine · 2026Review
- Assessment of Preprocedural Factors Associated with 5-Year Complete Response After Transarterial Radioembolization in Patients with Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma, volume II.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe retrospectively assessed the long-term outcomes of Yttrium-90 (
methodsWe included patients with HCC treated with
resultsAmong 142 patients (median age 66.8, cirrhotic 92.3%; M: F = 121:21), a median OS of 16.68 months was achieved, with a complete radiological response in 31% (44/142). OS was strongly correlated with radiological response (p < 0.001). Absorbed dose ≥ 234.6 Gy was associated with complete response (p = 0.017) but not with survival (p = 0.102). Rising alpha-fetoprotein levels (p = 0.017) and worsening Child-Pugh scores post-TARE (p = 0.044) were independent predictors of mortality.
conclusionA complete radiological response is crucial for long-term survival, highlighting the need for dosimetry optimization in TARE for HCC.
Indexed as
Identifiers
40056213What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.